EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost

George Dranitsaris, Aaron Peevyhouse, Tiffany Wood, Yuliya Kreychman, Heather Neuhalfen, Mehdi Moezi

Acta Haematologica · 2024

DOI: 10.1159/000533175 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Haematologica, 2024. Verfasst von George Dranitsaris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quality Care Cancer Alliance, Tacoma, Washington, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombopoietin, Hydrazines, Pyrazoles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic immune thrombocytopenia purpura (ITP) in adults is a serious autoimmune disease in which platelets are prematurely destroyed, leaving the patient vulnerable to bruising and bleeding. Initial treatment starts with corticosteroids. In patients who become resistant or intolerant to corticosteroids, the thrombopoietic agents (TPOs), consisting of romiplostim (ROM), eltrombopag (ELT), and avatrombopag (AVA), or the spleen tyrosine kinase inhibitor fostamatinib (FOS), are appropriate next lines of therapy. In this study, the comparative safety, effectiveness, and cost of care between fostamatinib and the TPOs were evaluated in a real-world setting.

Methods

A retrospective analysis of 17 community hematology practices across the USA was conducted to identify adult ITP patients who received one of the four agents. Data collection consisted of patient demographics, disease characteristics, as well as number and type of prior treatments. From the first day until the end of treatment, data were also collected on platelet (PLT) counts, adverse events, the use of rescue IVIG, platelet transfusions, and corticosteroids. Multivariable logistic regression analysis was used to compare PLT-related endpoints between agents.

Results

A sample of 179 ITP patients who had received at least one of the four agents was identified. This resulted in a final sample of 51, 87, 127, and 44 patients who received FOS, ELT, ROM, or AVA, respectively. At month six, there were no significant differences between FOS and the TPOs in terms of the proportion of patients with the PLT count being ≥30 × 103/μL, ≥50 × 103/μL as well as the proportion of patients whose PLT levels doubled relative to baseline. The frequency of thromboembolic events (TEs) was 3.9% in FOS patients compared to 9.2%, 4.7%, and 11.4% in the ELT, ROM, and AVA groups. The mean cost per patient with FOS was $99,209 (95% CI: $59,595–$115,074), compared to $92,426 (95% CI: $68,331–$115,519), $108,482 (95% CI: $84,782–$132,182), and $131,050 (95% CI: $83,327–$179,897) for ELT, ROM, or AVA, respectively.

Conclusions

In this real-world analysis, FOS was comparable to the TPOs in maintaining PLTs at clinically beneficial levels. Given these findings, the choice of therapy should be based on overall patient safety, preexisting risk factors for TEs, and cost effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombopoietinHydrazinesPyrazolesReceptors, FcMorpholinesOxazinesHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedPyridinesRecombinant Fusion ProteinsChronic DiseasePyrimidinesBenzoatesPlatelet CountCost-Benefit AnalysisTreatment OutcomeAminopyridinesThiazolesThiophenes

Stichwörter der Autor:innen

CostEffectivenessFostamatinibImmune thrombocytopenia purpuraReal-world evidenceSafetyThrombopoietin

Substanzen

ThrombopoietinfostamatinibHydrazinesPyrazolesReceptors, FcromiplostimMorpholinesOxazinesPyridineseltrombopag

Autor:innen und Institutionen

  • Quality Care Cancer Alliance, Tacoma, Washington, USA.
  • Department of Public Health, Syracuse University, Syracuse, New York, USA.
  • Rigel Pharmaceuticals, South San Francisco, California, USA.
  • Cancer Specialists of North Florida, Jacksonville, Florida, USA.

Zitieren

APA

Dranitsaris, G., Peevyhouse, A., Wood, T., Kreychman, Y., Neuhalfen, H., & Moezi, M. (2024). Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost. Acta Haematologica. https://doi.org/10.1159/000533175

Vancouver

Dranitsaris G, Peevyhouse A, Wood T, Kreychman Y, Neuhalfen H, Moezi M. Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost. Acta Haematologica. 2024. doi:10.1159/000533175

BibTeX
@article{Dranitsaris2024,
  author = {Dranitsaris, George and Peevyhouse, Aaron and Wood, Tiffany and Kreychman, Yuliya and Neuhalfen, Heather and Moezi, Mehdi},
  title = {Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000533175}
}
Kostenlos starten →